de Aguiar, Rodrigo Barbosa <br/><br/>
Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings.  [electronic resource] 

 -  Cancer letters  Feb 2016 
 - 151-60 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2015.11.030  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--metabolism<br/>Animals<br/>Antibodies, Monoclonal--metabolism<br/>Antigens, CD34--metabolism<br/>Cell Line, Tumor<br/>Fibroblast Growth Factor 2--antagonists & inhibitors<br/>Human Umbilical Vein Endothelial Cells--drug effects<br/>Immunohistochemistry<br/>Lung Neoplasms--blood supply<br/>Male<br/>Melanoma, Experimental--blood supply<br/>Mice, Inbred BALB C<br/>Mice, Inbred C57BL<br/>Molecular Targeted Therapy<br/>Neovascularization, Pathologic<br/>Neovascularization, Physiologic--drug effects<br/>Signal Transduction--drug effects<br/>Time Factors<br/>Tomography, Emission-Computed, Single-Photon<br/>Tomography, X-Ray Computed<br/>Tumor Burden